Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Photo: Igor Golovniov/SOPA Images/LightRocket via Getty Images
The FDA announced Tuesday it has issued an emergency use authorization for a new combination antibody drug from Eli Lilly that can treat mild to moderate COVID-19.
Why it matters: The treatment contains bamlanivimab and etesevimab which, administered together, can reduce the risk of hospitalizations and death by 70%, per an FDA statement. It can be used on patients at high risk of developing severe illnesses.
- With the risk of resistance emerging as new virus strains arise, "bamlanivimab and etesevimab together could potentially allow efficacy against a broader range of naturally occurring" variants of SARS-CoV-2, the virus that causes COVID-19, said Lilly chief scientific officer Daniel Skovronsky in a statement.
For the record: In November, the FDA issued an emergency use authorization for Lilly's antibody therapy bamlanivimab to treat mild to moderate coronavirus cases.
- Skovronsky, who's also president of Lilly Research Laboratories, said in Tuesday's statement that bamlanivimab "alone under emergency use authorization has already provided many people with an early treatment option that could prevent hospitalizations."
By the numbers: Lilly has in the first quarter of 2021 manufactured more than 250,000 doses of the combination treatment, which is given via a single intravenous infusion.
- The company plans to produce up to 1 million more by the middle of the year, per Lilly's statement.